Conditions: Cardiovascular Disease HIV Atherosclerosis Inflammation Statins, HMG-CoA HIV Infections
Keywords: Cardiovascular Disease HIV Atherosclerosis Inflammation Statins treatment experienced
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 40
Healthy volunteers: no

Brief summary:
In HIV patients, statin therapy will attenuate plaque inflammation, thus, making plaques less vulnerable, will deter plaque progression, and improve endothelial function. In addition to known cholesterol-lowering and C-reactive protein lowering effects, immunomodulatory effects of statins will lead to a shift from pro-inflammatory monocyte and T cell subsets to less atherogenic subpopulations.

Detailed description:

Arms:
arm 1: 20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months. arm 2: None

Interventions: intervention 1: atorvastatin intervention 2: Placebo
Intervention descriptions: intervention 1: 20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months. intervention 2: Placebo

Protocol document: